Other substances

Rifaximin

A semi-synthetic antibiotic.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
1
 AI-suggested references
0
 Clinical trials

General information

Rifaximin on PubChem

Marketed as

NORMIX; RIFACOL; XIFAXAN; XIFAXSAN

 

Structure image - Rifaximin

C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C

Supporting references

Link Tested on Impact factor Notes Publication date
Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches
Spike protein Small molecule In silico 		in silico 3.22

Predicted to inhibit the SARS-CoV-2 spike protein binding to the host's ACE2 receptor.

 Sep/24/2020

AI-suggested references

Link Publication date
Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2 S protein and human ACE2 interaction through virtual screening approaches
Nov/01/2020
Export (.csv)